1月29日晚间，归创通桥医疗科技股份有限公司(02190，以下简称"归创通桥"、"公司")发布2025年全年 业绩正面盈利预告。公司预期2025年全年净利润超过人民币2.4亿元，较去年同期大幅增长约139.4%； 营业收入超过人民币10.5亿元，同比增长约34.6%。 归创通桥表示，2025年公司业绩表现亮眼，主要受益于核心产品销售的强劲增长、海外业务的加速发展 以及运营效率的持续优化。报告期内，公司通桥麒麟血流导向装置、神经血管导丝、UltraFree药物洗脱 PTA球囊扩张导管、ZYLOX Swan静脉腔内射频闭合导管等产品销售收入均实现较快增长。国际业务方 面，公司海外市场销售收入同比增长超过100%，在德国、法国、意大利等重点国家市场的渗透率持续 提升。此外，在业务规模扩大的同时，公司持续推进运营效率提升，毛利率水平保持稳定，盈利能力进 一步增强。 2025年，归创通桥以"创新"与"国际化"为核心战略，持续推动业务布局与升级。报告期内，公司多款重 点创新产品相继获批上市。ZYLOX Mammoth大腔外周血栓抽吸导管、通桥飞龙颅内动脉瘤栓塞辅助支 架等产品实现商业化落地，并取得积极的市场表现。此外，公 ...

Core Viewpoint - Guichuang Tongqiao (02190) has seen a stock price increase of over 3%, currently trading at 25.52 HKD, following the approval of its intracranial aneurysm embolization assistive stent by the National Medical Products Administration (NMPA) [1] Group 1: Product Approval and Features - The Tongqiao Feilong intracranial aneurysm embolization assistive stent has received NMPA approval for market launch [1] - This stent is designed to be used in conjunction with embolization coils, specifically targeting the treatment of intracranial neurovascular diseases, providing a new and efficient clinical solution [1] - Compared to similar products on the market, the Tongqiao Feilong stent offers better wall adherence and visibility during procedures, enhancing operational safety and visibility [1] Group 2: Market Impact and Company Strategy - CITIC Securities (601066) highlights that the stent utilizes DFT material weaving technology, which allows for clear visibility throughout the procedure, aiding doctors in precise operational control [1] - The approval of the embolization assistive stent is expected to strengthen the company's product pipeline in the neurointerventional field, enhancing its overall solution offerings [1] - This development is anticipated to help the company increase its market share and maintain rapid growth in performance [1]